CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amphastar Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amphastar Pharmaceuticals Inc
11570 6th St
Phone: (909) 980-9484p:909 980-9484 RANCHO CUCAMONGA, CA  91730  United States Ticker: AMPHAMPH
Business Summary
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Operating Officer, Chief Scientist Mary Z.Luo 74 1/1/2005 1/1/1996
President, Chief Executive Officer, Chief Scientific Officer, Director Jack Y.Zhang 77 4/10/2020 1/1/1996
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International William J.Peters 56 8/4/2022 4/1/2014
7 additional Officers and Directors records available in full report.

Business Names
Business Name
AMPH
Amphastar Medication Co., LLC
Amphastar Nanjing Pharmaceuticals, Inc.
BAQSIMI®
Nanjing Letop Fine Chemistry Co., Ltd.

General Information
Number of Employees: 1,761 (As of 12/31/2023)
Outstanding Shares: 48,372,997 (As of 9/30/2024)
Shareholders: 120
Stock Exchange: NASD
Federal Tax Id: 330702205
Fax Number: (302) 655-5049
Email Address: info@amphastar.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024